Termed sarcopenic obesity, it is characterised by the concurrent decline in muscle mass and function along with increased levels of adipose tissue and is associated with higher risk of disability, metabolic dysfunction, comorbidities, e.g., T2D, chronic kidney disease, cardiovascular disease, and all-cause mortality [2, 3]
However, this increase in serotonin levels often results in weight gain
Conversely, if you are eating significantly less because of the combined nausea of the medications, you should watch for signs of low blood sugar (hypoglycemia), such as shakiness or dizziness
For example, the PBM offers options that cover both Zepbound and Wegovy, but this option is costlier for plan sponsors than its standard commercial formulary that excludes Zepbound